Dana Elias

Health Technology

Consumer Services

Profile

Dana Elias worked as a Program Director & Vice President at Andromeda Biotech Ltd.
from 2007 to 2010.
Prior to that, she held Principal positions at DeveloGen AG, Peptor Ltd, and Portman Pharmaceuticals, Inc. She received a graduate and doctorate degree from the Weizmann Institute of Science.

Former positions of Dana Elias

Companies	Position	End
Portman Pharmaceuticals, Inc.	Corporate Officer/Principal	-
DeveloGen AG DeveloGen AG Pharmaceuticals: MajorHealth Technology DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany.	Corporate Officer/Principal	-
Peptor Ltd	Corporate Officer/Principal	-
Andromeda Biotech Ltd. Andromeda Biotech Ltd. Pharmaceuticals: MajorHealth Technology Andromeda Biotech Ltd. develops treatment for autoimmune diabetes. The company was founded in 2007 and is headquartered in Rehovot, Israel.	Corporate Officer/Principal	-

See the detail of Dana Elias's experience

Training of Dana Elias

Weizmann Institute of Science

Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies